Objectives: Thrombocytopenia is common in neonatal intensive care units (NICU), with 18 to 35% of patients developing this problem before hospital discharge. It might be even more common among extremely low birth weight neonates (ELBW, p1000 g birth weight). However, little is known about thrombocytopenia in the ELBW population. We sought to determine the incidence, timing, causes, platelet transfusions given, and outcomes of thrombocytopenia among ELBW neonates. Results: Multiple platelet counts were obtained in all 284 (range, 4 to 441 platelet counts/patient). Of the 284, 208 (73%) had one or more platelet counts p150 000/ml. Most were detected during the first days of life; 80% were detected during the first week and only 20% were detected thereafter. Thrombcytopenia was more common among the smallest patients; 85% incidence among those p800 g, 60% among those 801 to 900 g, and 53% among those 901 to 1000 g. Platelet transfusions were given to 129 of the 208 thrombocytopenic neonates. More than 90% were given prophylactically (the patient was not bleeding). The mortality rate among those that received platelet transfusions was twice that of those that received no platelet transfusions (P<0.01). In 48% of cases, the cause of the thrombocytopenia went undiagnosed. The most common explanations were being small for gestational age or delivered to a hypertensive mother, DIC, bacterial infection, fungal infection, and necrotizing enterocolitis, respectively.
Introduction
Thrombocytopenia is common in the neonatal intensive care unit (NICU). Previous reports estimate that 18 to 35% of all patients admitted to a NICU will have one or more platelet counts p150 000/ml at some time during their NICU stay. [1] [2] [3] [4] [5] McPherson and Juul 6 recently observed that the risk of thrombocytopenia in the NICU is highest among the most preterm infants, but we found no previous studies focusing on the incidence, timing, causes, and outcomes of thrombocytopenia among extremely low birth weight (ELBW) neonates.
To better understand thrombocytopenia in the ELBW population, we performed an historic cohort analysis of neonates cared for in the four Intermountain Healthcare (IHC) NICUs during a 2-year period. From archived electronic records and from paper chart analysis we accessed all platelet counts obtained on these patients. When a count p150 000/ml was identified, we determined the day of life the thrombocytopenia was first recognized, the duration of the thrombocytopenia, the tests used to discover the underlying causes, the underlying causes that were ascribed, the use of platelet transfusions, and the mortality rates.
Methods
Data were collected as deidentified limited data sets from archived IHC records. The information collected was limited to the complete blood counts and the information displayed in tables and figures of this report. Data were obtained for patients admitted to the NICU at McKay-Dee Hospital, Ogden, UT, LDS Hospital, Salt Lake City, UT, Primary Children's Medical Center, Salt Lake City, UT, and Utah Valley Regional Medical Center, Provo, UT, with a date of birth from 1 January 2003 to 31 December 2004, and with a birth weight of p1000 g. Extremely low birth weight neonates who died in the first 48 h after admission to the NICU were excluded from the analysis because not all of their data are included in the IHC archived data repository.
The program used for data collection was a modified subsystem of 'clinical workstation'. The 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. The data were collected from the electronic medical record, case mix, pharmacy, and laboratory systems. Trained and designated clinical personnel entered additional data. Data were managed and accessed by authorized data analysts. In addition, the medical records (paper) of 208 neonates with thrombocytopenia were reviewed by the authors to determine the laboratory tests performed to assess the cause of the thrombocytopenia, to determine the stated reasons for ordering each platelet transfusion, and to record what was listed as the likely underlying explanation for the thrombocytopenia. The IHC Institutional Review Board approved the study.
Descriptive statistics were calculated using Statit (Corvallis, OR, USA). Means and standard deviations were used to express values in groups that were normally distributed, and medians and ranges to express values in groups that were not. Differences in categorical variables were assessed using the w 2 -test. A Student t-test was used to assess continuous variables. Statistical significance was set as P<0.05. All hypotheses were two-tailed. In 58% of the thrombocytopenic ELBW neonates, the thrombocytopenia was detected in the first 3 days after birth (Figure 1 ). Only 20% of those who developed thrombocytopenia had this first recognized after the first week of life. Six cases (3%) were not detected until seven weeks or more.
Results
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Thrombocytopenia was more common in the lowest birth weight groups (Figure 2 ). It was found in 85% of those weighing p800 g at birth, in 60% of those weighing 801 to 900 g, and in 53% of those weighing 901 to 1000 g. The duration of thrombocytopenia ranged from less than 1 day to 50 days. Of the 208, 21 (10%) had either very transient thrombocytopenia, or had an erroneously low platelet count, because a repeat count performed within 24 h was normal without an intervening platelet transfusion. However, 90% of those with a count <150 000/ml continued to have thrombocytopenia for the next 2 days or more.
The lowest recorded platelet count was <20 000/ml in 9% of the thrombocytopenic patients; it was p50 000/ml in 38% of the thrombocytopenic patients, and it was p100 000/ml in 77%. The remaining 23% had mild thrombocytopenia, with the lowest recorded platelet count between 101 000 and 149 000/ml. The mortality rate did not correlate with the lowest recorded platelet count. Among those with the most severe thrombocytopenia (<20 000/ml) 16.7% died, among those with a lowest count in the range of 20 to 50 000/ml 16.4% died, among those with a lowest count in the range of 51 to 100 000/ml 19.7% died, and among those with a lowest count in the range of 101 to 149 000/ml 14.6% died. The mortality rates among ELBW neonates who did vs did not receive platelet transfusions are shown in Table 1 . Seventy-five neonates had no thrombocytopenia and no platelet transfusions. Seventy-nine others had thrombocytopenia but no platelet transfusions. One patient (not listed in the table) had a platelet transfusion but was not thrombocytopenic. Thus, 154 ELBW neonates received no platelet transfusions; the mortality rate in this group was 12%. One hundred and twenty-nine were thrombocytopenic and received one or more platelet transfusions (range, 1 to 51 transfusions/patient). The mortality rate in this group was 23% (P<0.01 vs those who received no platelet transfusions, Table 2 ). Most of the patients who developed thrombocytopenia and died, did so while their platelet count was still low (Table 1) .
The platelet counts that preceded 357 platelet transfusions are shown in Table 2 . For patients who had multiple platelet transfusions, information was collected only for their first five platelet transfusions. The minority of platelet transfusions (8%) were ordered for patients with clinical hemorrhage; most were ordered when no record of clinical hemorrhage was found among the physician or nursing notes. The majority (61%) of these latter prophylactic platelet transfusions were ordered when the platelet count was between 50 000 and 99 000/ml. In all, 28% of the prophylactic transfusions were ordered when the platelet count was in the range of 20 000 to 49 000/ml, and only 2.8% of the platelet transfusions were ordered when the platelet count was <20 000/ml.
Of the thrombocytopenic neonates, 56% had a bacterial culture performed to evaluate the underlying cause of the thrombo- Figure 2 Thrombocytopenia as related to birth weight. The incidence of thrombocytopenia among 284 extremely low birth weight (ELBW) neonates, as related to birth weight. The number of platelet transfusions administered and the mortality rates are shown for 284 ELBW neonates.
Thrombocytopenia in ELBW neonates RD Christensen et al cytopenia. Also, 49% had a DIC screen preformed, 10% had cytomegalovirus (CMV) cultures performed, 3% had lineograms or other imaging studies in an attempt to detect thrombi, and 2% had chromosomes or other genetic testing as part of the search for an etiology of the thrombocytopenia. Of the thrombocytopenic neonates, 2% had viral cultures or viral titers (other than CMV) drawn, and <1% had antiplatelet antibody testing performed.
The explanations given for the thrombocytopenia are shown in Table 3 . Almost half had no explanation discovered. The most commonly applied explanation for thrombocytopenia was that the patient was SGA or was delivered after PIH. None had a diagnosis made of neonatal alloimmune thrombocytopenia, maternal autoimmune thrombocytopenia, viral infection, or drug-associated thrombocytopenia. The likely underlying causes, explaining the presence of thrombocytopenia among 208 ELBW neonates, are shown. In some instances, more than one contributing factor was ascribed (for instance, both bacterial sepsis and DIC). Therefore, the sum of each column exceeds 100%. *One trisomy 18 and one TAR syndrome. **Right atrial thrombus associated with a peripherally inserted central venous catheter. Abbreviations: CMV, cytomegalovirus; ELBW, extremely low birth weight neonates; NEC, necrotizing enterocolitis.
Discussion
Less than 1% of babies in a well-baby nursery are expected to have a platelet count <150 000/ml. 7 However, in a NICU thrombocytopenia is common, with a reported incidence of 18 to 35%. [1] [2] [3] [4] [5] On the basis of our experience, we speculated that ELBW neonates have a yet higher incidence of thrombocytopenia. Indeed, in the present study, we observed that 73% of ELBW neonates had one or more platelet counts <150 000/ml. Extremely low birth weight neonates who died before reaching 48 h of age were not included in our study because of incomplete data recording in our system. Perhaps ignoring these produced a bias in our findings. We speculate that thrombocytopenia is exceedingly common among the ELBW neonates who die in the first 2 days, owing to the effect on platelet count of early onset infection, thrombi, DIC, and severe hemorrhages. Thus, we speculate that the incidence of thrombocytopenia we report (73%) is if anything an underestimate of the overall incidence of thrombocytopenia in ELBW neonates.
In some instances, the diagnosis of neonatal thrombocytopenia can be erroneous, as when a blood sample has platelet clumping that goes unrecognized. 8 Sometimes a platelet count is low, but a repeat count within the next 24 h is normal. About 10% of the thrombocytopenia we observed was in this category. It is not possible to determine whether this 10% were low owing to laboratory errors, or alternatively whether these patients were indeed transiently thrombocytopenic. However, we judge this was a minor confounder in this study, because in 90% of the cases the thrombocytopenia persisted for between 48 h and several weeks. Thus, the great majority of the thrombocytopenia we observed was likely to be real, not erroneous.
Neonatal thrombocytopenia can have its onset either before or after birth. Owing to the retrospective nature of this study, it is not possible to know how many of these ELBW neonates had a prenatal onset of thrombocytopenia. Not all patients had a platelet count obtained immediately after delivery. Furthermore, there was no prespecified list of tests to be performed in order to assess the underlying causes of the thrombocytopenia or measure its duration. However, we speculate that the majority of cases were either of prenatal onset or owing to factors arising within the first days after birth. We base this on the finding that nearly 50% of cases were recognized on the first day of life, 80% were recognized within the first week, and only 20% were identified thereafter.
Neonatal thrombocytopenia has been classified as severe, moderately severe, or mild, depending on the lowest platelet count recorded. Of the thrombocytopenic ELBW neonates we observed, 23% had mild thrombocytopenia with nadir platelet counts between 101 000 and 149 000/ml. It has been claimed that counts in this range do not increase the risk of hemorrhage. 9 This supposition is based on the observation that the bleeding time is not prolonged until the platelet count falls to <100 000/ml. 10, 11 However, it is not clear whether this reasoning is accurate in ELBW neonates, and thus the clinical significance of platelet counts between 100 000 and 150 000/ml in this population is unknown. Until better information is available, we recommend repeating counts found in this range, and reserving additional evaluative tests for patients with counts <100 000/ml. 12 Of the thrombocytopenic ELBW neonates we observed, 39% had nadir platelet counts between 51 000 and 100 000/ml and thus could be classified as having moderately severe thrombocytopenia. The magnitude of the hemostatic deficiency created in an ELBW neonate by a count in this range is not known. Neonates who are SGA or were delivered to women with PIH are at an increased risk of developing thrombocytopenia, 3, 4, 13 and these varieties generally have a nadir count in the range of 50 000 to 100 000/ml. We observed that 55 of 124 ELBW neonates with early recognition (first 3 days of life) thrombocytopenia were thought to have thrombocytopenia on the basis of PIH or SGA. Curiously, 21 of 88 with thrombocytopenia recognized after the first 3 days were also thought to have thrombocytopenia on the basis of PIH or SGA, although it is doubtful that PIH or SGA status can cause lateappearing thrombocytopenia.
Of the thrombocytopenic ELBW neonates we observed, 38% had nadir platelet counts below 50 000/ml, and thus could be classified as having severe thrombocytopenia. Previous reports examining thrombocytopenia among the general NICU population indicate that 25% of cases have counts below 50 000/ml. 1,2 Perhaps our 38% figure suggests that severe thrombocytopenia is over-represented among ELBW neonates.
In about half of the cases of thrombocytopenia among general NICU patients, an underlying explanation for the thrombocytopenia is not found. [2] [3] [4] [5] [6] We observed that about this same proportion of thrombocytopenic ELBW neonates had no explanation recognized for their thrombocytopenia. In otherwise well-appearing term babies with thrombocytopenia, the diagnosis is likely to be neonatal alloimmune thrombocytopenia or owing to maternal autoimmune disease, 14,15 but we found no documented cases of either of these varieties. We speculate that the lack of immune-mediated cases could be the result of inadequate testing in this population. Similarly, infection with bacteria, viruses, or fungi can cause thrombocytopenia, [16] [17] [18] [19] [20] [21] and we speculate that such infections may have been responsible for more cases that were documented. DIC can result in thrombocytopenia, 20 and we found this diagnosed in 40 of the 208 cases. Congenital abnormalities of platelet production, owing to inborn genetic errors, can cause thrombocytopenia, but we found only two (one trisomy 18 and one TAR syndrome) among the 208.
Platelet transfusions are recommended for neonates who have low platelet counts and clinical bleeding. 22 They are also recommended as prophylaxis against bleeding if the count falls sufficiently low. [23] [24] [25] Precisely how low to permit a platelet count to fall in an ELBW neonate before ordering a platelet transfusion is not known. We found that platelet transfusions were nearly always given for prophylaxis against bleeding rather than to treat active bleeding. We identified no consistent criteria for ordering prophylactic platelet transfusions. We did find that those given platelet transfusions had a mortality rate twice that of those who received no platelet transfusions. We speculate that this increase in mortality rate is related to the underlying illnesses of those who received platelet transfusions, as opposed to being due to a toxic effect of the transfusions.
In this analysis of ELBW neonates, we found thrombocytopenia to be very common; more than twice as common as reported among the general NICU population. [1] [2] [3] [4] [5] We observed that thrombocytopenia was most common among the patients of lowest birth weight, that the majority of the cases were identified in the first week of life, and that the mortality rate of those who received a platelet transfusion was twice that of those who did not. We also observed that more than half of the cases had no specific diagnosis identified as a cause of the thrombocytopenia, although no systematic protocol for evaluating the cause was used. Perhaps more thorough investigation would have revealed the underlying cause in many cases, as the lack may have been the result of an incomplete evaluation. New efforts to improve the outcome of ELBW neonates should focus on this common problem of thrombocytopenia. The underlying causes of this problem should be clarified, safe lower limits for platelet counts in this population should be defined, and strategies for prevention and treatment should be devised.
